News

FDA gives NGN-401, potential Rett gene therapy, RMAT status

NGN-401, Neurogene‘s experimental gene therapy for Rett syndrome, was designated a regenerative medicine advanced therapy (RMAT) by the U.S. Food and Drug Administration (FDA). Based on preliminary data from an ongoing Phase 1/2 trial (NCT05898620), which is testing the gene therapy in girls with Rett, the…

IRSF names 3 centers of excellence for Rett clinical care

The International Rett Syndrome Foundation (IRSF) designated three new clinics as centers of excellence, saying they provide best-in-class clinical care for people with Rett syndrome. The designation comes with funding support from the foundation and integration into IRSF’s Center of Excellence Network, which now has 21 clinics…

Family support weighs heavily in doctors’ decisions on ventilation

When clinicians have to decide whether to recommend invasive ventilation for adolescents with Rett syndrome, parental and familial support are the biggest factors in their decision, a recent study reports. Many teenagers with Rett syndrome have difficulty breathing, and clinicians for some may recommend invasive ventilation via a tracheostomy…